Morris Innovative

What Morris Innovative does

Morris Innovative is a privately held, for-profit medical device company founded in 2002 and headquartered in Bloomington, Indiana. The company develops vascular closure devices — products used to seal puncture sites in arteries following catheter-based procedures such as cardiac catheterization, interventional radiology, and endovascular interventions. The company serves the healthcare provider market, specifically hospitals, catheterization labs, and interventional physicians who perform vascular access procedures, though no specific customer logos, distribution channels, or pricing information are disclosed in the available data.

The company operates at a small scale, with a headcount of 11-50 employees, and has raised approximately $4.7M in disclosed funding across two rounds: $1.18M in October 2009 and $3.5M in November 2017. Investors and lead investors for both rounds are undisclosed. Leadership consists of CEO Mark Bartosh and co-founder/director Andy DeNardo. No additional management team information, board composition, or institutional backers are reported in the source data.

Available commercial and operational data is sparse: no revenue figures, no product-level specifications, no FDA clearance history, no patents, no partnerships, no M&A activity, and no geographic footprint are disclosed. The company website content captured is minimal (effectively a tracking beacon only), reflecting either a thin public web presence or limited publicly indexed content. Given the duration since the last disclosed funding round (over eight years) and the absence of any subsequent strategic signals, the company's current commercial status, growth momentum, and trajectory are difficult to assess from public sources.

Name

Morris Innovative

Website

https://morrisinnovative.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Morris Innovative is a Bloomington, Indiana-based private medical device company founded in 2002 that develops vascular closure devices for healthcare providers performing vascular access procedures.

Ownership category

akta.pro rank

Headquarters

HQ city

Bloomington

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Core offering

Morris Innovative manufactures vascular closure devices intended for medical use to seal puncture sites in arteries or veins following catheter-based procedures. The devices are physical products produced by the company and sold to clinical and hospital customers. The company's core competency is the design and production of these vascular hemostasis solutions.

Differentiator

Problem solved

Functional benefit

Products and services

• Vascular Closure Devices Vascular closure devices manufactured by Morris Innovative for medical use to achieve hemostasis after catheterization procedures; intended for hospitals, catheterization laboratories, and specialty clinical sites.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights1 record

Broad incumbents

• Becton, Dickinson and Company (BD): BD markets vascular access and procedural products and is a major supplier to hospitals and catheterization labs. Although not exclusively a vascular closure vendor, BD's scale and access relationships make it a credible adjacent incumbent that competes for procedural workflow budgets in the same cath-lab environment.
• Abbott (Vascular Closure): Abbott markets vascular closure devices (e.g., the Perclose family via its structural heart/vascular division) and dominates the cardiovascular device space. It is the most significant direct market incumbent against which any vascular closure specialist must compete on clinical evidence, sales force reach, and hospital contracting.
• Teleflex (Mynx / Vascade): Teleflex entered vascular closure through the acquisition of Essential Medical (Mynx) and also markets Vascade. The company competes with vascular closure specialists across both absorbable and plug-based technologies and exemplifies the M&A exit pathway available to small closure companies.
• Cardinal Health (Cordis — formerly AccessClosure / MynxGrip franchise): Cardinal Health's Cordis franchise markets MynxGrip and other access management products acquired from AccessClosure. It is a broad incumbent in the catheter lab supplies and access management space, providing the second major commercial competitor context for Morris Innovative.
• Haemonetics (Vascade): Haemonetics markets the Vascade vascular closure system, offering a direct competitive product in the same clinical indication. Although Haemonetics is broader-focused in blood management, Vascade sits squarely in the closure category and competes for hospital formulary share.

Emerging players

• InSeal Medical: InSeal Medical is an early-stage specialist developing a closure technology for large-bore arterial punctures, particularly for structural heart and endovascular procedures. Its product focus mirrors Morris Innovative's vascular closure niche and represents a similarly sized emerging competitor.
• Cardiva Medical (acquired by Haemonetics): Cardiva Medical developed the Vascade vascular closure system before being acquired by Haemonetics, representing a real-world precedent of a small vascular closure specialist being acquired as a portfolio extension — a relevant comparable outcome to Morris Innovative's potential strategic path.
• Vivasure Medical: Vivasure Medical is a privately held developer of large-hole vascular closure devices, focusing on closure for transcatheter procedures (e.g., TAVR, EVAR). It overlaps with Morris Innovative's vascular closure focus on differentiated clinical use cases such as large-bore access closure.

Regional players

• Medi-Tate (acquired by Olympus / Welllead): Medi-Tate developed minimally invasive urological and access closure devices; comparable positioning as a niche specialist with a single clinical focus, illustrating the small-company M&A pathway relevant to Morris Innovative's strategic landscape.

Direct peers

• Terumo (Angio-Seal): Terumo's Angio-Seal is one of the most widely used vascular closure devices worldwide and competes head-to-head with any standalone closure developer. Terumo combines the device with broad interventional cardiology sales coverage, making it the closest direct peer for Morris Innovative's clinical specialty.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/morris-innovative

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Morris Innovative